COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Pharmacokinetic (PK), Pharmacodynamic (PD) and Tolerability of Osilodrostat in Pediatric Patients With Cushing's Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03708900
Recruitment Status : Recruiting
First Posted : October 17, 2018
Last Update Posted : June 30, 2020
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )

Brief Summary:
Multicenter, open-label, non-comparative study to evaluate the pharmacokinetics, pharmacodynamics, and tolerability of osilodrostat in children and adolescent patients with Cushing's disease.

Condition or disease Intervention/treatment Phase
Cushing's Disease Drug: LCI699 Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 12 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase II, Multicenter, Open-label, Non-comparative Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Tolerability of Osilodrostat in Children and Adolescent Patients With Cushing's Disease
Estimated Study Start Date : October 30, 2020
Estimated Primary Completion Date : February 21, 2023
Estimated Study Completion Date : November 29, 2023

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: LCI699 (osilodrostat)
Subjects with cushing's disease taking LCI699 (osilodrostat)
Drug: LCI699
osilodrostat (LCI699) is in the form of tablets for oral administration and comes in the following tablet strengths: 1 milligram (mg), 5 mg, and 10mg.
Other Name: osilodrostat

Primary Outcome Measures :
  1. Core Study: Evaluate the pharmacokinetics (PK) of osilodrostat using Pharmacokinetic parameter - Cmax - of osilodrostat up to Week 12 in children and adolescents 6 to less than 18 years of age with Cusihing's Disease [ Time Frame: up to Week 12 ]
    evaluate the pharmacokinetics (PK) by Cmax of osilodrostat in children and adolescents 6 to less than 18 years of age with Cushing's Disease

  2. Core Study: Evaluate the pharmacokinetics of osilodrostat using Pharmacokinetic parameter - Ctrough - of osilodrostat up to Week 12 in children and adolescents 6 to less than 18 years of age with Cushing's Disease [ Time Frame: up to Week 12 ]
    evaluate the pharmacokinetics (PK) by Ctrough of osilodrostat in children and adolescents 6 to less than 18 years of age with Cushing's Disease

Secondary Outcome Measures :
  1. Core Study: Percentage of patients with normal mean urinary free cortisol (mUFC) at week 6 and week 12 (or end of treatment) [ Time Frame: week 6, week 12 (or end of treatment) ]
    The assessment in the core period will be done by taking the percentage of patients with normal mUFC at week 6 and week 12 (or end of treatment).

  2. Core Study: Change from baseline in mean urinary free cortisol (mUFC) during the core study period [ Time Frame: Baseline, 12 weeks ]
    The assessment will be done by comparison of change from the baseline in mUFC during core study period on patients

  3. Extension: Efficacy of osilodrostat as measured by mUFC levels up to Month 12 [ Time Frame: up to month 12 ]
    The assessment of efficacy of osilodrostat to be measured by mUFC levels up to 12 months on patients

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   6 Years to 18 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Cushing's disease of endogenous origin: Who have failed surgery (or) who are awaiting surgery (or) for whom surgery is not an immediate option.
  • The diagnosis of Cushing's disease must be confirmed by each of the following:

    • The clinical criterion of decreasing growth percentiles with increasing weight (as evidenced by the presence of a contrast in height and BMI standard deviation (SD) scores, defined as height standard deviation score (SDS) < 0 and BMI SDS > 0, and a strong clinical suspicion of Cushing's disease, such as photographic evidence of a change in facial appearance);
    • Abnormal low-dose (0.5 mg Q6h x 48 hours) dexamethasone suppression test, defined as plasma cortisol levels > 1.8 mcg/dl, at time point 48 hours after the first dose of dexamethasone;
    • Measurable morning ACTH levels, assessed before 10 am;
    • Two 24-hour urinary free cortisol values > 1.3 x ULN
    • If the dexamethasone suppression test does not meet the above mentioned criteria, the diagnosis of Cushing's disease may be confirmed by the following: Midnight serum cortisol levels > upper limit of normal (ULN), assessed while the patient is sleeping and after pre-cannulation (OR) two samples of late night salivary cortisol greater than ULN for the assay
  • Able to swallow study drug tablets (not crushed or split)
  • Parents or legal guardians able to provide consent/assent

Exclusion Criteria:

  • Patients with macroadenoma complicated by compressive symptoms (requiring urgent surgical intervention) or at high risk for compressive symptoms due to mass effect of tumor (concern of corticotroph tumor progression)
  • Hypercortisolism not due to Cushing's disease
  • Insufficient washout period from any other medication used to lower cortisol levels (5 half-lives of any drug)
  • Use of other investigational drugs at the time of enrollment, or within 30 days, or prior to completion of a wash-out duration that is at least 5 half- lives of the drug, at the time of enrollment, whichever is longer. Local regulations may require a longer wash-out period or specify other limitations for participation in an investigational trial, in which case they will be applicable as well.
  • Body weight <30kg

Other protocol-defined inclusion/exclusion may apply.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03708900

Layout table for location contacts
Contact: Novartis Pharmaceuticals 1-888-669-6682
Contact: Novartis Pharmaceuticals +41613241111

Layout table for location information
Novartis Investigative Site Recruiting
Jette, Brussel, Belgium, 1090
Novartis Investigative Site Recruiting
Varna, Bulgaria, 9010
Novartis Investigative Site Recruiting
Pisa, PI, Italy, 56124
Novartis Investigative Site Recruiting
Ljubljana, Slovenia, 1525
United Kingdom
Novartis Investigative Site Recruiting
Liverpool, United Kingdom, L12 2AP
Novartis Investigative Site Recruiting
London, United Kingdom, E11BB
Sponsors and Collaborators
Novartis Pharmaceuticals
Layout table for investigator information
Study Director: Novartis Pharmaceuticals Novartis Pharmaceuticals
Layout table for additonal information
Responsible Party: Novartis Pharmaceuticals Identifier: NCT03708900    
Other Study ID Numbers: CLCI699C2203
2018-001522-25 ( EudraCT Number )
First Posted: October 17, 2018    Key Record Dates
Last Update Posted: June 30, 2020
Last Verified: June 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided
Plan Description:

Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.

This trial data availability is according to the criteria and process described on

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Novartis ( Novartis Pharmaceuticals ):
Cushing's disease (CD)
Pituitary Gland
Adrenocorticotropic Hormone (ACTH)
Urinary Free Cortisol (UFC)
mean Urinary Free Cortisol (mUFC)
Additional relevant MeSH terms:
Layout table for MeSH terms
ACTH-Secreting Pituitary Adenoma
Pituitary ACTH Hypersecretion
Pituitary Diseases
Hypothalamic Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Endocrine System Diseases
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Pituitary Neoplasms
Endocrine Gland Neoplasms
Neoplasms by Site